1211540-74-7

Usage

Uses

Used in Organic Synthesis:
(5-Bromo-3-nitropyridin-2-yl)acetic acid ethyl ester is used as an intermediate in organic synthesis for the production of various chemical compounds. Its unique structure allows it to be a versatile building block in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (5-Bromo-3-nitropyridin-2-yl)acetic acid ethyl ester is used as a starting material for the development of new drugs. Its potential pharmacological activities make it a promising candidate for the creation of novel therapeutic agents.
Used as a Reagent in Chemical Reactions:
(5-Bromo-3-nitropyridin-2-yl)acetic acid ethyl ester is utilized as a reagent in chemical reactions, particularly in the formation of carbon-carbon bonds. Its ability to participate in such reactions makes it a valuable tool in the synthesis of various organic compounds.
Used in Drug Discovery:
(5-Bromo-3-nitropyridin-2-yl)acetic acid ethyl ester is employed in drug discovery processes to identify and develop new pharmaceutical agents. Its potential use in the development of new drugs highlights its importance in the advancement of medicinal chemistry.

Upstream product

• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 6148-64-7 ethyl potassium malonate 
• 911434-04-3 2-(5-bromo-3-nitro-pyridin-2-yl)-malonic acid diethyl ester 

Downstream Products

• 1379312-86-3 ethyl 2-(3-Amino-5-bromopyridin-2-yl)acetate 
• 1190319-62-0 6-bromo-1,3-dihydro-2H-pyrrolo[3,2-b]pyridin-2-one 

Relevant academic research and scientific papers

TRIAZINE DERIVATIVE HAVING EGFR INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF

Disclosed are a triazine derivative having EGFR inhibitory activity, a preparation method therefor and use thereof. In particular, disclosed are an EGFR inhibitor having a structure of formula (I), a preparation method therefor, a pharmaceutical composition containing same, use thereof for preparing the EGFR inhibitor, and use thereof in preparing medicaments for treating and/or preventing cancers, tumors or metastatic diseases at least partially related to insertion, deletion or other mutation of EGFR exon 20, and in particular use thereof in preparing medicaments for treating and/or preventing hyperproliferative diseases and diseases inducing cell death disorders. The definition of each substituent of formula (I) is the same as that in the description.

1,3-dihydro-2H-pyrrolo[3,2-b]pyridin-2-one derivative and medical application thereof

The invention discloses a 1,3-dihydro-2H-pyrrolo[3,2-b]pyridin-2-one derivative and medical application thereof. A compound is a compound shown in a formula I, or a pharmaceutically acceptable salt ora stereoisomer or a tautomer thereof, wherein R1-R4 is defined by the specification.

SPIROCYCLIC INDOLINES AS IL-17 MODULATORS

A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) is shown below:

HETEROCYCLIC COMPOUND

A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.

Lead optimization of 1,4-azaindoles as antimycobacterial agents

In a previous report, we described the discovery of 1,4-azaindoles, a chemical series with excellent in vitro and in vivo antimycobacterial potency through noncovalent inhibition of decaprenylphosphoryl-β-d-ribose-2′- epimerase (DprE1). Nevertheless, high mouse metabolic turnover and phosphodiesterase 6 (PDE6) off-target activity limited its advancement. Herein, we report lead optimization of this series, culminating in potent, metabolically stable compounds that have a robust pharmacokinetic profile without any PDE6 liability. Furthermore, we demonstrate efficacy for 1,4-azaindoles in a rat chronic TB infection model. We believe that compounds from the 1,4-azaindole series are suitable for in vivo combination and safety studies.

Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors

Structure-based rational design led to the synthesis of a novel series of potent PI3K inhibitors. The optimized pyrrolopyridine analogue 63 was a potent and selective PI3Kβ/δ dual inhibitor that displayed suitable physicochemical properties and pharmacokinetic profile for animal studies. Analogue 63 was found to be efficacious in animal models of inflammation including a keyhole limpet hemocyanin (KLH) study and a collagen-induced arthritis (CIA) disease model of rheumatoid arthritis. These studies highlight the potential therapeutic value of inhibiting both the PI3Kβ and δ isoforms in the treatment of a number of inflammatory diseases.